Anemia and Erythropoeitin and Iron Channel: Hypertension, Dialysis and Clinical Nephrology (HDCN): Renal Kidney Disease Electronic Journal / Hypertension, Dialysis, Nephrology Information Server

Nissenson	Fishbane
Germain	Provenzano

Achieving Control: Optimizing the Management of CKD-Anemia
Allen R. Nissenson, MD; Steven Fishbane, MD; Michael J. Germain, MD; Robert Provenzano, MD
(CME Symposium (Synermed-Penn State), March, 2008).
Nissenson: What is the difference between target and achieved hemoglobin? What did the 2007 KDOQI anemia update recommend and what were the results of the KDOQI meta-analysis? Fishbane: In CKD, at what point should one start to treat a low Hb? What is the approach to ESA hyporesponsiveness? How can one dose iron and ESA in such a way to limit Hb variability? Why is Hb variability relevant? Germain: What are the various drugs available to stimulate red cell production? What are their pharmacokinetics? To what extent is pharmacologic half-life associated with the time course of Hb response, especially with less frequent dosing? Is Hb variability different with shorter and longer half-life drugs? How frequently should Hb be monitored? What are good strategies for ESA dosing adjustment? Provenzano: What are areas were care of predialysis CKD patients might be improved? What resources do such patients utilize? What is the cost of providing care to them? What is the opportunity for providing care to this population and maintain reimbursement to have a viable practice? What is the RPA CKD management toolkit, and how can it help in the care of these patients? What are services, revenue, and costs of a CKD clinic model?

(more...)

J03

Secondary analysis of CHOIR data suggests that high EPO doses, rather than high Hb per se, associated with mortality.

J28

Bill to approve pathway for FDA approvals of biosimilars advocated as saving billions of dollars.

J26

Testing of athletes for illicit EPO use has high rate of false negatives.

M27

AMAG Pharmaceuticals signs agreement with 3SBio to commercialize ferumoxytol in China.

M21

Former Amgen executive Dr. Robert Brenner moves to AMAG.

M21

Protein structure is deciphered of steap3, a protein that regulates iron absorption in the gut.

M06

PNAS: Erythropoietin promoter polymorphisms associated with diabetic retinopathy and progression to ESRD.

M05

ASN Renal Week abstract archives 2003-2006 now available on-line in .pdf format.

A28

New JAMA study to highlight CV risk of blood substitutes; FDA under renewed pressure.

A15

CMS adopts 26 new CPMs effective April 1, 2008

A13

Genetic mutation causes iron-resistant iron-deficiency anemia by turning on hepcidin.

A04

AMAG Pharma presents data on new iron supplement at NKF Spring Clinical Meeting.

A04

Affymax presents Phase 2 Hematide data at NKF Spring Clinical Meeting in Dallas.

M27

U.S. judge seeks expert advice on Amgen-Roche license.

M20

Vitamin C recycling in human red cells explained via glut-1.

Industry

Advances

Emphasis

archive

	The New KDOQI Guidelines for Anemia, a Debate: Should the Upper Hgb Limit be 12 or 13 g/dL? ASN Renal Week 2006
	A New Tri-Partite Approach to Anemia ASN Renal Week 2006
	Practical Considerations for the Management of Anemia in Nephrology Patients: Searching for an Improved Erythropoietic Treatment. RPA Satellite Symposium, 2006
	Anemia in the PD Patient (Michael V. Rocco, MD, MS, FACP; Allen R. Nissenson, MD, FACP; Chaim Charytan, MD; David B. Van Wyck, MD) ADC 2006 (audio only)
	Practical Considerations for the Management of Anemia in Nephrology Patients: Searching for an Improved Erythropoietic Treatment (Pereira, Wish, Aronoff) ANNA 2006
	Anemia Management in CKD: Improving Anemia Management (target: nurses) (Reed, Copeland) ANNA 2006
	Evidence-Based Anemia Management (target: nurses) (McCarley) ANNA 2006
	A Balanced Approach to Anemia Therapy: IV Iron and EPO (target: nurses) (Easom, Bowe) ANNA 2006
	New Developments in Anemia and Erythropoietin Science (Ganz, Lin, Singh) ASN Renal Week 2005 (audio only)
	Anemia in Renal Disease: Update and Case Discussion (Berns, Van Wyck) ASN Renal Week 2005
	The Role of Iron Deficiency in Anemia Management: Key Controversies (Wish, Zager, Kalantar-Zadeh, Agarwal) ASN Renal Week 2005
	Anemia and Iron Management: Addressing Challenges and Generating Solutions (target: nurses) (Easom, Volkert) ANNA 2005
	Complications of Anemia and the CKD Patient (target: nurses) (Petroff) ANNA 2005
	Treating Patients With IV Iron Therapy: Special Considerations (target: nurses) (Fishbane, Warady) ANNA 2005
	Maximizing Patient Outcomes Through IV Iron Therapy and Appropriate Iron Measures (Agarwal, Coyne) RRI Sat 2005

	Should patients with venous thromboembolism be screened for thrombophilia? Am J Med (Jun 2008)
	High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol (May 2008)
	Technology insight: biomarker development in acute kidney injury-what can we anticipate? Nature Clin Pract Nephrol (Mar 2008)
	The optimal hemoglobin in dialysis patients -- a critical review Semin Dial (Feb 2008)
	Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure Nature Clin Pract Nephrol (Jan 2008)
	The target hemoglobin level in patients on dialysis (Singh AJ) Dial Transplant (Jul 2007)
	Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer (FR Khuri) N Engl J Med (Jun 2007)
	Clinical aspects of iron use in the anemia of kidney disease (Hoerl) JASN (02-2007)
	Clinical aspects of iron use in the anemia of kidney disease JASN 02-07
	Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR NDT (02-07)
	(2006 Pharma )Year in Review (Michele B. Kaufman, PharmD, RPh) Dial-Transplant 12-06